Cutaneous squamous cell carcinoma
Also known as: Cutaneous SCC, cSCC, Squamous cell carcinoma of the skin, Keratinocyte carcinoma, squamous subtype
Cutaneous squamous cell carcinoma (cSCC) is a common skin cancer arising from epidermal keratinocytes. It requires definitive medical diagnosis through biopsy, followed by risk assessment and standard oncological treatment like surgery. Traditional Chinese Medicine (TCM) does not treat the malignancy itself, nor should it ever delay conventional care. Instead, it may be used to support general wellbeing by addressing secondary symptoms like distress, fatigue, or poor sleep. The evidence cited here includes a histopathology imaging study, laboratory work, and animal models, but no clinical trials evaluating acupuncture or herbal medicine in patients with cSCC. The TCM patterns listed provide a framework for symptom management, not cancer staging, and must be coordinated with the patient's medical team.
Plain-English one-pager you can print or hand to a patient. Free, no sign-in needed.
Lifestyle & Diet
- •Utilise mechanical photoprotection including shade and protective clothing, and apply broad-spectrum sunscreen; avoid all forms of deliberate ultraviolet exposure.
- •Prioritise all scheduled dermatological reviews and report evolving lesions to a medical practitioner immediately rather than deferring to a TCM consultation.
- •Adhere strictly to post-surgical wound-care protocols; refrain from applying herbal topicals, thermotherapy, or corrosive substances to lesions or surgical sites.
- •Maintain regular nutritional intake, adequate hydration, and moderate physical activity as tolerated; request a dietetic referral if appetite decreases or involuntary weight loss occurs.
Cautions & Contraindications
- •Do not needle, massage deeply, cup, apply moxibustion or place herbal applications over a suspected tumour, biopsy site, unhealed surgical wound or damaged irradiated skin. This is a conservative procedural precaution; reference 1 concerns diagnostic classification and does not test needling safety.[]
- •Do not use laboratory Syk or HSP27 findings to justify herbal anticancer treatment, alter prescribed oncology medicines or postpone definitive care. These studies concern cells and, for HSP27, mouse models; they establish neither patient benefit nor herbal interaction safety.[,]
When to reassess or seek care again
Before adjunctive care, document the medical treatment plan, medicines, wound status and baseline fatigue, distress and sleep ratings on 0–10 scales. Review after 2–4 weeks or 2–4 visits using the same ratings, sleep duration and functional goals. Stop or revise ineffective adjunctive care; refer promptly for deterioration, unexplained weight loss or new lesion-related symptoms. Never use symptom improvement as evidence of tumour response or defer oncology surveillance.
Explore more diseases
Sources & Further Reading
Clinical guidance, red flags and safety notes on this page draw on the following current sources alongside the classical references above.
- Photodiagnosis and photodynamic therapy · 2026
- Experimental dermatology · 2026
- Journal of translational medicine · 2026
- BioFactors (Oxford, England) · 2026
Educational reference for licensed practitioners. Not a substitute for individual clinical assessment. Refer to conventional care for any red-flag or undiagnosed presentation.
